Can lenalidomide play a role in the management of scleritis?

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Al Jafar, Hassan A ^a   Abul, Nadia ^b   Kumar, Niranjan ^b   Al Awadhi, Adel ^c  

^a AL AMIRI HOSPITAL   (Kuwait)

^b Al Bahar Eye Center   (Kuwait)

^c KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HEMOGLOBIN; LENALIDOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHEST INFECTION; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; LABORATORY TEST; LOW DRUG DOSE; MAINTENANCE THERAPY; MYELODYSPLASTIC SYNDROME; PALLOR; PANCYTOPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; SCLERITIS; SYMPTOM; TREATMENT DURATION; WEAKNESS;

EID: 84880083668     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-009092     Document Type: Article

References (15)

1. Okhravi N, Odufuwa B, McCluskey P, et al. Major review. Scleritis Surv Ophthalmol 2005;50:351-63.
2. Ahn SJ, Oh JY, Kim MK, et al. Clinical features, predisposing factors and treatment outcomes of scleritis in the Korean population. Korean J Ophthalmol 2010;24:331-5.
3. Keino H, Watanabe T, Taki W, et al. Clinical features and visual outcomes of Japanese patients with scleritis. Br J Ophthalmol 2010;94:1459-63.
4. Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Scleritis therapy. Ophthalmology 2012;119:51-8.
5. Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol 2011;4:139-41.
6. Mariz JM, Esteves GV. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Curr Opin Oncol 2012;24(Suppl 2):S3-12.
7. Vallet S, Witzens-Harig M, Jaeger D, et al. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother 2012;13:473-94.
8. Al-Jafar HA, Al-Azmi S, Qassem JA, et al . Complete remission of del(5q) myelodysplastic syndrome after 7 days of lenalidomide therapy gives an alert!. Case Rep Oncol 2012;5:586-91.
9. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology 1994;101:389-96. (Pubitemid 24077041)
10. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol 1976;60:163-91.
11. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infl iximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6. (Pubitemid 38183244)
12. Adès L, Fenaux P. Immunomodulating drugs in myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2011;2011:556-60.
13. Martiniani R, Di Loreto V, Di Sano C, et al. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol 2012;2012:842945.
14. Wobus M, Benath G, Ferrer RA, et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol 2012;40:867-76.
15. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702.